BECN1 and intrahepatic cholangiocarcinoma: For ICC, previous study reported that Beclin 1 was strongly expressed in 24.1% (26/108) of overall patients, and Beclin 1 low expression was correlated with an inferior 3-year OS (22.4 VS 35.6%) and PFS, though the subsequent Cox regression analysis confirmed that Beclin 1 was not an independent indicator to PFS [26].